{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.8","value":"320"},{"groupId":"OG001","spread":"32.3","value":"1486"}]}],"title":"Cycle 1, Day 16 (n = 13, 9)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.5","value":"584"},{"groupId":"OG001","spread":"132.8","value":"2086"}]}],"title":"Cycle 2, Day 1 (n = 10, 8)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with normal renal function received carfilzomib 20 mg/m² IV on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles.","id":"OG000","title":"Normal Renal Function"},{"description":"Participants with ESRD received carfilzomib 20 mg/m² IV on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles.","id":"OG001","title":"End Stage Renal Disease"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK evaluable population; One participant was excluded due to samples taken from the infusion arm, distal to the infusion site. \"n\" indicates the number of participants included in the analyses at each time point.","reportingStatus":"POSTED","timeFrame":"Cycle 1, day 16 and cycle 2, day 1 at predose, 15 minutes post start of infusion, immediately before the end of infusion, and at 5, 15, and 30 minutes, and 1, 2, and 4 hours after the end of the infusion.","title":"Area Under the Concentration Time Curve From Time 0 to Last Concentration (AUC0-last) for Metabolite PR-389/M14","type":"SECONDARY","unitOfMeasure":"ng*h/mL"}